| |
Tuesday, April 30, 2024 | 2pm ET / 11am PT Liquid biopsies have shown tremendous progress for the early detection of cancer and for treatment monitoring, but still have limitations. The inclusion of protein glycosylation can help. Join us to learn more about the latest solutions for leveraging AI and machine learning to accelerate data processing, overcome current barriers, and provide crucial information. Register now. 
|
|
Today’s Big NewsApr 23, 2024 |
| By Angus Liu Giovanni Caforio, M.D., is lining up a new gig soon after handing all his Bristol Myers Squibb leadership roles over in March. The recent Big Pharma CEO, known for steering the $74 billion acquisition of Celgene, has been proposed as the new chair at Novartis for 2025. |
|
|
|
By Nick Paul Taylor Sanofi’s $3.7 billion Principia Biopharma buyout has delivered a phase 3 victory. The BTK inhibitor moved the needle in a clotting disorder, clearing Sanofi to file for approval of a “multi-indication blockbuster” that it predicts could contribute to more than 10 billion euros ($11 billion) of drug launch sales. |
By Conor Hale Profluent has staked a claim at the intersection of some of the buzziest terms in biopharma. The protein-focused AI startup believes its large language models can help extend the reach of CRISPR gene editing tools. |
By Fraiser Kansteiner As the BIOSECURE Act threatens to upend relationships with Chinese contractors and western biopharma companies operating in the U.S., Novartis has elected not to adopt a “wait and see” attitude. |
|
Tuesday, May 7, 2024 | 11 ET / 8 am PT This webinar dives into challenges and strategies in commercializing cell and gene therapies. Experts explore process standardization, treatment tracking tech, network channel strategy, and scaling for commercial success in this promising but complex field. Register now. 
|
|
By Max Bayer Incyte is dolloping another deal onto its 2024 partnership plate, buying San Diego-based Escient Pharmaceuticals for $750 million. |
By Nick Paul Taylor Eisai has recently outlined a range of ways to kick-start Leqembi’s lackluster launch, from increasing the number of neurology account specialists to adding a subcutaneous option. But a Reuters report suggests the company faces a more fundamental problem: Physicians still see Alzheimer’s disease as untreatable. |
By Conor Hale The FDA delivered a Class I recall label for the issue late last week, spanning 145 affected Covidien SonarMed monitors and hundreds of its sensor packages. Medtronic first notified users March 25. |
By Angus Liu After a merger and an FDA rejection, celebrity businessman and biotech entrepreneur Patrick Soon-Shiong’s ImmunityBio has landed the company’s first U.S. approval in the cancer immunotherapy Anktiva. |
By Annalee Armstrong After Alpine Immune Sciences presented initial data for the kidney disease therapy povetacicept at a conference in November 2023, the biotech's confidential data room became the most exclusive club in biotech. |
By Andrea Park After a short stint away from Inizio Evoke’s family of health marketing agencies, Stephanie DeViteri has returned to head up the North American branch of Inizio Evoke Comms. |
By Nick Paul Taylor The cuts keep coming at BenevolentAI. Eleven months after restructuring, the AI-enabled drug developer is pulling another pivot, axing plans to launch software products, laying off another 30% of staff and closing its U.S. office. |
By Andrea Park There’s a new life-sciences-focused consulting firm in town. Founded by a duo with about half a century’s worth of experience in biopharma and medtech between them, Santander Pharma Consulting—no relation to the bank—stepped into the spotlight with a launch announcement Tuesday. |
By Helen Floersh A new study adds to the case that long-term daily aspirin use may prevent colorectal tumors from developing or spreading in some patients, with potential implications for future drugs. |
By Andrea Park After kicking off a global expansion project last fall, independent healthcare agency The Bloc has been on a creative team hiring spree. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we are joined by Annalee Armstrong, Senior Editor at Fierce Biotech, and Ben Adams, Senior Editor of Fierce Pharma Marketing, to discuss Fierce's take on March Madness. |
|
|---|
|
|
|
Wednesday, May 13, 2024 | 10 ET / 7 am PT This webinar unveils AI's transformative role in life sciences, presented by industry experts. Learn how AI process automation expedites drug development, ensures regulatory compliance, enhances communication, and boosts collaboration. Register now. 
|
|
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
Whitepaper Discover the secrets behind successful patient engagement Sponsored by: ProofPilot |
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
eBook Unlock the future of monoclonal antibody (mAb) manufacturing with a complete guide to enhancing productivity and quality for exceptional outcomes. Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
